The selective BCL-2 inhibitor venetoclax (VEN; ABT-199) demonstrated efficacy both preclinically and clinically in a broad range of hematologic neoplasms and is currently being evaluated for its clinical implication in ALL [8]. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.